Connect Biopharma Secures $20.2M to Advance Asthma and COPD Drug

SAN DIEGO, CA – March 30, 2026 – Connect Biopharma Holdings Limited has secured approximately $20.2 million in a private placement, a critical injection of capital that extends its financial runway into the second half of 2027 and ensures the continued development of its promising inflammatory disease pipeline.

The San Diego-based clinical-stage company announced it had entered into a securities purchase agreement to sell 6,130,000 of its ordinary shares at a price of $3.25 per share. The financing was led by Panacea Venture, the company’s largest existing investor, and included participation from other new and U.S.-based healthcare-focused investors. The move signals strong insider and specialist confidence in the company's lead asset, rademikibart, an antibody treatment for asthma and COPD.

A Financial Lifeline in a Challenging Market

This successful fundraising effort arrives as a significant achievement in a notoriously difficult funding environment for clinical-stage biotechnology firms. Many companies in the sector have struggled to raise capital amidst market volatility and increased investor scrutiny. Connect Biopharma's ability to secure this financing not only strengthens its balance sheet but also serves as a testament to investor belief in its scientific platform and strategic direction.

The net proceeds are earmarked for the research and development of its clinical programs, primarily rademikibart. Before this financing, the company reported having $54.8 million in cash, cash equivalents, and short-term investments as of September 30, 2025. With total operating expenses running at $17.7 million for the third quarter of 2025, the new infusion provides crucial breathing room. This capital extends the company's operational runway into the second half of 2027, a critical period during which it expects to report key clinical trial data.

The financing comes on the heels of a remarkable run for the company's stock (NASDAQ: CNTB), which had surged 128% in the six months leading up to the announcement. While such rallies can attract investor interest, the underlying financial health of pre-revenue biotechs remains a key concern. Some financial analyses, for instance, have pointed to the inherent risks of high cash-burn companies, underscoring the importance of strategic capital raises like this one. By securing this funding, Connect Biopharma has directly addressed concerns about its cash runway and de-risked its near-term operational plans.

Fueling the Rademikibart Engine

The fresh capital will primarily fuel the advancement of rademikibart, a next-generation antibody designed to target the IL-4Rα receptor. This pathway is a well-established driver of Type 2 inflammation, which is implicated in a range of diseases, including asthma, COPD, and atopic dermatitis.

Connect Biopharma is specifically targeting areas of high unmet medical need: acute exacerbations of asthma and COPD. These are sudden, severe flare-ups that can lead to hospitalization and significant patient distress. The company initiated parallel Phase 2 clinical trials for these indications in the second quarter of 2025, with topline results eagerly anticipated in the second half of 2026.

What sets rademikibart apart, according to the company's clinical data, is its potential for a rapid onset of action. In previous studies for asthma, the drug demonstrated the ability to produce statistically significant improvements in lung function—measured by forced expiratory volume (FEV1)—within just 24 hours. This rapid improvement, which was sustained over weeks, could be a major differentiator in a market currently dominated by treatments that may take longer to show effects. The market for IL-4Rα inhibitors is significant, with blockbusters like Dupixent (dupilumab) setting a high bar. For rademikibart to succeed, demonstrating a clear clinical advantage, such as faster relief for patients suffering from acute attacks, will be paramount.

Strategic Confidence and Global Ambitions

The structure of the financing deal speaks volumes about the confidence in Connect Biopharma's strategy. The leadership of Panacea Venture, its largest shareholder, in the private placement is a powerful endorsement from a knowledgeable insider. The participation of other specialized healthcare investors further validates the potential of the company's pipeline.

Beyond its internal development, Connect Biopharma has pursued a savvy global strategy. A key component of this is its exclusive license and collaboration agreement with Simcere Pharmaceutical Co., Ltd. for the development and commercialization of rademikibart in Greater China. This partnership has already begun to bear fruit. In July 2025, Simcere submitted a New Drug Application (NDA) to Chinese regulators for rademikibart for the treatment of moderate-to-severe atopic dermatitis, a common inflammatory skin condition. The application was accepted, and results from the underlying Phase 3 study were slated for presentation at a major dermatology conference.

This partnership not only provides external validation of rademikibart's potential but also creates a potential future revenue stream. Under the agreement, Connect Biopharma is eligible for up to approximately $110 million in remaining milestone payments, in addition to tiered royalties on net sales in the vast Chinese market. This approach allows the company to monetize its asset in a major territory while focusing its own resources on global development for asthma and COPD.

With its financial future secured for the next few years, Connect Biopharma is now squarely focused on execution. The coming months will be defined by the steady progress of its clinical trials. The data readout expected in the latter half of 2026 will be a critical inflection point for the company, its investors, and potentially for the millions of patients seeking faster, more effective treatments for debilitating respiratory flare-ups.